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OBJECTIVES: To analyze the accuracy of an AMCP budget
impact model designed to forecast the ﬁrst-year use of a new
osteoporosis therapy in a managed care/pharmacy beneﬁt setting
and describe characteristics of patients who initiated therapy.
METHODS: Following AMCP guidelines, a model was devel-
oped to predict ﬁrst-year (2003) use and treatment costs for a
new osteoporosis therapy (teriparatide) using plan characteris-
tics (total number of insured lives, age and sex distribution) 
as model inputs. Using administrative claims data from an
employer database (n = 3.5 million), predicted versus actual use
and treatment costs were compared for eight health care plans
of varying types (indemnity, PPO, POS, HMO). Demographic
characteristics and medical histories of patients initiating the new
therapy were compared to other osteoporosis patients in the
database (ICD-9 CM = 733.0x). RESULTS: The model predicted
a total of 131 patients would initiate therapy; the actual number
was 133. The number was overestimated in four plans with the
margin of error ranging from +113% (34 predicted vs. 16 actual)
to -30% (40 predicted vs. 57 actual). The difference in predicted
versus actual treatment costs ranged from -$19,527 to
+$103,315. Patients initiating the new therapy were on average
older compared to other osteoporosis patients (P < 0.001). In the
year prior to initiating the new therapy, these patients also had
more outpatient, inpatient, ofﬁce, and prescription drug claims
per month and were more likely to have seen a specialist or have
had an osteoporotic fracture compared to other osteoporosis
patients (P < 0.001). CONCLUSION: AMCP-style models for
newly approved therapies can provide important insight to
health plan administrators when making formulary decisions
during the initial year of therapy availability. Updating such
models by incorporating inputs based on patient characteristics
and actual ﬁrst-year use of therapy may yield more accurate esti-
mates of future use and treatment costs.
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OBJECTIVES: Objectives were: 1) to determine the effectiveness
of osteoporosis medications; 2) to identify risk factors and 
other covariates that predict osteoporotic fractures; and 3) to
determine the cost-effectiveness of osteoporosis medications.
METHODS: A retrospective cohort study was conducted using
DOD claims from ﬁscal years 2000 to 2003. Using an intent-to-
treat study design, a total of 49,851 women >= age 50 were fol-
lowed. Differences in effectiveness (fracture/no fracture) were
determined by both logistic and direct Cox proportional hazard
regressions. To assess cost-effectiveness, a net-beneﬁt regression
method was employed. RESULTS: Findings showed that the
three-year cumulative incidence of an osteoporotic fracture in
this cohort was 2.5% (0.4% in patients without an osteoporo-
sis diagnosis; 6.1% in patients with an osteoporosis diagnosis).
The medication effectiveness results obtained from both regres-
sion models were consistent and suggested that women treated
with the combination of alendronate and HRT were at lower
risk for any fracture, hip fracture, and vertebral fracture when
compared to no treatment, while comparisons of the individual
medications with no treatment did not show a signiﬁcant
decrease in risk. Variables that signiﬁcantly increased the risk of
fracture were: prior fracture, increasing age, and oral corticos-
teroid use >= year. The net-beneﬁt regression showed that the use
of osteoporosis medications was not cost-effective overall in the
short-term compared to no treatment. However, among high-risk
populations, such as patients with a prior osteoporotic fracture
or those >= 65, medications became more cost-effective. CON-
CLUSIONS: Combination therapy with HRT and alendronate
was more effective than no treatment in DOD women >= 50.
None of the treatment options were cost-effective in the short-
term for the overall population, but some were more cost-
effective in subsets of high-risk patients. The results of this study
were potentially inﬂuenced by the presence of selection bias,
therefore propensity scoring will be conducted.
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OBJECTIVES: To estimate the cost-effectiveness of bisphospho-
nates (Alendronate, Risedronate and cyclical Etidronate) or
Raloxifene versus no therapy over a two-year treatment period
in patients with osteoporosis and in those with previous fragility
fracture. METHODS: A decision analytic model using local cost
data and clinical data from meta-analysis or randomised con-
trolled trial was developed to evaluate cost-effectiveness of the
various interventions. The main perspective of the economic
evaluation was that of health care purchaser. Therefore, only
direct health care costs were considered in the evaluation. A 
two-year time horizon was chosen as clinical data about the efﬁ-
cacy of the various interventions considered are available.
RESULTS: The results of the evaluation showed that it is not
cost-effective to treat all patients. However, the analysis per-
formed did not consider indirect and intangible cost due to 
the perspective used in the evaluation. Alendronate and cyclical
etidronate appeared to be the most cost-effective agents to
prevent hip fracture and vertebra fracture respectively. The
ranking and magnitude of the incremental cost-effectiveness
ratio of the various treatments did not change by the sensitivity
analyses using the 95% CI of the efﬁcacy data. CONCLUSION:
If treatment is indicated, it would be prudent to consider cycli-
cal etidronate if the risk of hip fracture is low. Raloxifene can
be considered if patient will beneﬁt from other non-osteoporo-
sis indication in this group of patients. However, in patients who
have high risk of hip fracture, alendronate or risedronate will be
more cost-effective.
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OBJECTIVES: Male osteoporosis is traditionally under-
diagnosed. In the US, two-million men have osteoporosis and
